Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ovarian Cancer Market Report Overview

The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan.

Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian epithelium. Each year in the US, more than 19,700 women receive a new diagnosis of ovarian cancer.

Ovarian Cancer Market Outlook 2022-2032 ($ Billion)
Ovarian Cancer Market Outlook 2022-2032 ($ Billion)
Buy the Full Report to Know More About the Ovarian Cancer Market Forecast
Download a Free Sample Report

The ovarian cancer market research report offers an overview of ovarian cancer, including its epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying smart business strategies. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.

Market Size (2022) $3.3 billion
CAGR (2022-2032) >1%
Key Countries (7MM) ·       The US

·       5EU

·       Japan

Key Drug Classes ·       PARP Inhibitors

·       Chemotherapy

·       Hormonal Therapy

·       Targeted Therapy

·       VEGF Inhibitor

Key Sponsors ·       National Cancer Institute, The US

·       AstraZeneca

·       Incyte Corp

·       Tesaro Inc

·       Pfizer Inc

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Ovarian Cancer Market Dynamics

The rising sales of ImmunoGen’s Elahere is one of the most impactful drivers of growth for the ovarian cancer market. Elahere is anticipated to launch in the 5EU and Japan during the forecast period. However, Factors such as high costs associated with treatments hamper the market growth in the forecast period.

Buy the Full Report for Additional Insights on the Key Ovarian Cancer Market Dynamics
Download a Free Sample Report

Ovarian Cancer Market Segmentation by Country

The key countries in the ovarian cancer market are the US, 5EU, and Japan. In 2022, the US dominated the total ovarian cancer market share. The dominance of the US within the 7MM is due to its larger population suffering from ovarian cancer and higher drug prices in the country.

Ovarian Cancer Market Analysis by Country, 2022 (%)
Ovarian Cancer Market Analysis by Country, 2022 (%)
Buy the Full Report for Country-Wise Insights on the Ovarian Cancer Market
Download a Free Sample Report

Ovarian Cancer Market Segmentation by Drug Classes

During 2022, there were several drug classes in the ovarian cancer market including PARP inhibitors, chemotherapy, hormonal therapy, targeted therapy, and VEGF inhibitor among others. In 2022, PARP inhibitors contributed the highest sales to the ovarian cancer market.

Ovarian Cancer Market Analysis by Drug Classes, 2022 (%)
Ovarian Cancer Market Analysis by Drug Classes, 2022 (%)
Buy the Full Report for Drug-Class Insights on the Ovarian Cancer Market
Download a Free Sample Report

Ovarian Cancer Market Segmentation by Sponsors

The key sponsors in the ovarian cancer market are the National Cancer Institute, The US, AstraZeneca, Incyte Corp, Tesaro Inc., and Pfizer Inc. among others.  Lynparza’s manufacturer, AstraZeneca, has been a leading sponsor of clinical trials in ovarian cancer.

Ovarian Cancer Market Analysis by Sponsors, 2023 (%)
Ovarian Cancer Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for Sponsor-Wise Insights on the Ovarian Cancer Market
Download a Free Sample Report

Segments Covered in this Report

Ovarian Cancer Market Country Outlook ($ Billion, 2022-2032)

  • The US
  • 5EU
  • Japan

Ovarian Cancer Market Drug Classes Outlook (%, 2022-2032)

  • PARP Inhibitors
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • VEGF Inhibitor

Scope

  • Overview of Ovarian Cancer, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized Ovarian Cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Ovarian Cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Ovarian Cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
  • Analysis of the current and future market competition in the global Ovarian Cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecast includes 7 countries

Forecast covers 2022-2032

Reasons to Buy

  • Review the pipeline products and technologies and identify the companies with the most robust pipeline to develop and design your in-licensing and out-licensing strategies.
  • Understand the trends shaping and driving the ovarian cancer therapeutics market to develop business strategies.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Advenchen Laboratories
Alkermes
AstraZeneca Plc
Bristol Myers Squibb
Clovis Oncology
Corcept Therapeutics
Eisai
Genentech
Genelux Corp
GlaxoSmithKline
Merck & Co
Mersana Therapeutics
OncoQuest Inc
Ono Pharmaceuticals
Roche
Sutro Biopharma Inc
Verastem Oncology
Zentalis Pharmaceuticals

Table of Contents

1. Preface

1.1. Contents

1.2. Related Reports

1.3. Abbreviations

2. Executive Summary

3. Disease Overview

3.1. Overview of Ovarian Cancer

3.2. Ovarian Cancer Strengths, Weaknesses, Opportunities, and Threats Analysis

3.3. Classification of Ovarian Cancer

4. Epidemiology

4.1. Diagnosed Incident Cases of Ovarian Cancer, Women, Ages ≥18 Years, 2022–32

4.2. Age-Specific Diagnosed Incident Cases of Ovarian Cancer, Women, 2022

4.3. Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype, Women, Ages ≥18 Years, 2022

4.4. Diagnosed Incident Cases of Ovarian Cancer by FIGO Stage, Women, Ages ≥18 Years, 2022

4.5. Five-Year Diagnosed Prevalent Cases, Women, Ages ≥18 Years, 2022

4.6. Sources and Methodology for Diagnosed Incident Cases of Ovarian Cancer

4.7. Sources and Methodology

4.8. Sources and Methodology – Diagnosed Incidence of Ovarian Cancer

4.9. Sources and Methodology – Five-Year Diagnosed Prevalent Cases of Ovarian Cancer

4.10. Sources and Methodology – Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype

5. Current Treatment Options

5.1. Ovarian Cancer Treatment Algorithm

5.2. Treatment Paradigm – First-Line Therapy

5.3. Treatment Paradigm – Platinum-Status

5.4. Current Treatment Options

5.5. Product Profile of VEGF Inhibitor (Avastin)

5.6. Product Profiles of PARP Inhibitors (Lynparza, Rubraca, Zejula)

5.7. Product Profile of Kinase Inhibitor (Rozlytrek)

5.8. Product Profile of Antibody-Drug Conjugate (Elahere)

6. Unmet Needs and Opportunities

7. R&D Strategies

7.1. Trends in Ovarian Cancer Clinical Trial Design

7.2. Trends in Ovarian Cancer Deal-Making

8. Pipeline Assessment

8.1. Ovarian Cancer Pipeline Overview

8.2. Late-Stage Pipeline Agents for Ovarian Cancer

8.3. Product Profile of Verastem Oncology’s avutometinib + defactinib

8.4. Product Profile of Zentalis Pharmaceuticals’s azenosertib

8.5. Product Profile of Novartis’s Femara (letrozole)

8.6. Product Profile of Alkermes’s nemvaleukin

8.7. Product Profile of Corcept Therapeutics’s relacorilant

8.8. Product Profile of Genelux’s Olvi-vec (olvimulogene nanivacirepvec)

8.9. Product Profile of AstraZeneca’s cediranib maleate

8.10. Product Profile of Advenchen Laboratories’s catequentinib

8.11. Product Profile of AstraZeneca’s Imfinzi (durvalumab)

8.12. Product Profile of Merck & Co’s Keytruda (pembrolizumab)

8.13. Product Profile of Roche’s Tecentriq (atezolizumab)

8.14. Product Profile of GSK’s Jemperli (dostarlimab)

8.15. Product Profile of Bristol Myers Squibb / Ono Pharmaceuticals’s Opdivo (nivolumab)

8.16. Product Profile of OncoQuest’s oregovomab

8.17. Product Profile of Eisai / Bristol Myers Squibb’s farletuzumab ecteribulin

8.18. Product Profile of Mersana Therapeutics’s upifitamab rilsodotin

8.19. Product Profile of Sutro Biopharma’s luveltamab tazevibulin

9. Market Outlook

9.1. Ovarian Cancer Clinical Trials by Trial Sponsors

9.2. Ovarian Cancer Market Forecast

9.3. Market Drivers and Barriers

10. Appendix

10.1. Primary Research – KOL Information

10.2. About the Authors

11. Contact Us

Frequently asked questions

Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 standard reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 in real time.

  • Access a live Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.